Immunomedics (IMMU) this morning announced that it has entered into an agreement with Johnson & Johnson (JNJ) to provide detailing services to J&J for erdafitinib in the U.S. through Q1 of 2020, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes the deal will provide incremental revenue to Immunomedics while allowing the company to keep its sacituzumab-trained sales team on board while offsetting some of the costs. Further, the Q1 of 2020 termination suggests a potential timeline for a sacituzumab re-filing and approval, says Catanzaro, who notes Immunomedics has not yet provided guidance. The analyst remains comfortable with his mid-2020 approval timing for sacituzumab and keeps an Overweight rating on Immunomedics with a $20 price target.